Cargando…
Commentary: Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA
Autores principales: | Ruan, Xiulu, Luo, Jin Jun, Kaye, Alan David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233663/ https://www.ncbi.nlm.nih.gov/pubmed/28133451 http://dx.doi.org/10.3389/fpsyt.2016.00210 |
Ejemplares similares
-
The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
por: Fornaro, Michele, et al.
Publicado: (2019) -
Commentary: A Neural Basis for the Acquired Capacity for Suicide
por: Gonda, Xenia
Publicado: (2017) -
Are sedatives and hypnotics associated with increased suicide risk of suicide in the elderly?
por: Carlsten, Anders, et al.
Publicado: (2009) -
Commentary: Duty to Warn: Antidepressant Black Box Suicidality Warning is Empirically Justified
por: Goodman, Wayne K., et al.
Publicado: (2020) -
Physicians’ attitudes toward hypnotics for insomnia: A questionnaire-based study
por: Takeshima, Masahiro, et al.
Publicado: (2023)